What is Zion Pharma?
Founded in 2018, Zion Pharma operates as a specialized clinical-stage biotechnology enterprise with research hubs in Suzhou and Shanghai. The company distinguishes itself through a rigorous focus on small molecule, anti-tumoral agents. By leveraging deep expertise in drug metabolism and pharmacokinetics (DMPK), Zion Pharma is advancing a robust pipeline of first-in-class and best-in-class compounds. Their therapeutic focus is strategically aligned with high-impact targets that drive tumor inhibition, specifically addressing complex biological pathways such as ATM, KRAS G12D, and SMARCA2 (BRM). This technical proficiency positions the firm as a significant player in the competitive landscape of precision oncology.
How much funding has Zion Pharma raised?
Zion Pharma has raised a total of $20M across 1 funding round:
Series A
$20M
Series A (2020): $20M with participation from Qiming Venture Partners, Sherpa Healthcare Partners, and Medfine Capital
Key Investors in Zion Pharma
Qiming Venture Partners
A leading venture capital firm with a strong track record in the healthcare and life sciences sectors, focusing on early-stage and growth-stage investments.
Sherpa Healthcare Partners
A specialized investment firm dedicated to supporting innovative healthcare companies and medical technology advancements.
Medfine Capital
A strategic investment group focused on providing capital and operational support to emerging biotech and pharmaceutical ventures.
What's next for Zion Pharma?
The infusion of capital will likely be directed toward advancing the company's lead candidates through critical clinical milestones. As Zion Pharma transitions from early-stage research to more mature clinical trials, the focus will shift toward validating the efficacy of its proprietary compounds in human subjects. The strategic backing from prominent venture firms provides not only the necessary liquidity for high-cost R&D operations but also the institutional guidance required to navigate the complex regulatory environment of global drug development. Future growth will depend on the successful translation of their DMPK-driven discovery approach into tangible therapeutic outcomes, potentially setting the stage for future licensing agreements or strategic partnerships with larger pharmaceutical entities.
See full Zion Pharma company page
